Trial Profile
Double-Blind, Double-Dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Jan 2017
Price :
$35
*
At a glance
- Drugs Budesonide (Primary) ; Mesalazine (Primary)
- Indications Crohn's disease
- Focus Pharmacogenomic; Therapeutic Use
- Sponsors Dr Falk Pharma
- 15 Aug 2008 New trial record.